布鲁克partners with ANPC to support major new frontline response to combat the COVID-19 threat

布鲁克is proud to partner with Australian National Phenome Centre (ANPC) at Murdoch University to support the work of their researchers into the COVID-19 pandemic threat.

由世界知名现象先驱和院士教授杰里米·尼科尔森（Jeremy Nicholson）领导的ANPC团队，并与南大都会卫生服务公司Covid-19响应团队和更广泛的西澳大利亚州（WA）医疗保健社区合作，为一项重大的研究和诊断项目推出了一项重大的研究和诊断项目bob电竞官方网站更好地理解和预测COVID-19的严重程度的变化，并确定影响其在个体的致病性的复杂遗传，环境和生活方式相互作用。后来，他们将参与新型抗病毒剂的临床试验，并在可用的疫苗时进行预测，以预测响应者/非反应结果。

Accelerating time to diagnosis

目的是在加速的时间范围内提供诊断和预后解决方案。最重要的是，需要迅速评估受感染患者严重程度的风险，以帮助指导和优化临床患者途径。ANPC的研究人员将使用一系列最新的Avance IVDr nuclear magnetic resonance (NMR)and timsTOF Pro, Impact II andSolarix MR mass spectrometry (MS)instrumentation from Bruker, as well as data modeling approaches, to perform broad and deep metabolic analysis of the molecular, physical and biochemical characteristics of blood plasma and urine samples to create informative translational models. These models will predict variation in the severity of the disease and help understand differential responses to therapeutic interventions.

Professor Nicholson said: “At the ANPC, we are dedicating 100% of our resources to the COVID-19 fight for at least a year. This is the greatest emergent healthcare challenge on the planet and there is no better equipped metabolic lab in Australia, or possibly anywhere in the world, to undertake this type of investigative work in an excellent clinical and hospital framework.

“Linked to our genomics team, led by Professor Simon Mallal and Associate Professor Mark Watson, we’re setting out to identify specific biomarkers of the disease to figure out who has it, how we can detect it and stratify patients by severity risk, and assess the real time patient responses to treatments.”:

Scientific partnership to drive clinical research

Frank H. Laukien, Ph.D, President and CEO of Bruker Corporation, commented: “We are strongly committed to supporting Professor Nicholson and his team scientifically and technically. The comprehensive COVID-19 clinical research plan at Murdoch University into metabolic biomarker patterns of diseases, prognosis, and treatment response is exceptional.

“特别是，我希望该团队能够很快找到基于证据的临床方案，以减少Covid-19的'2阶段'的死亡率，并威胁生命的下呼吸道感染。Medical science needs to determine urgently whether broad spectrum antibiotics and/or immunosuppressants improve survival statistics in ‘phase 2’, when viral pneumonia, potential bacterial pneumonia or ventilator-associated pneumonia (VAP), as well as lung inflammation due to our own immune systems’ cytokine storms, appear to create a very dangerous set of co-morbidities.”

Unique bio sample collection capability

该项目将看到ANPC携手工作with Professor Merrilee Needham of Murdoch University and Notre Dame University, and Professor Toby Richards of the University of Western Australia, who are bringing together the top doctors and researchers from WA through the Western Australian Health Translation Network (WAHTN) led by Professor Gary Geelhood for the COVID-19 Response Team.

预计将同意所有新的Covid-19患者接受入院测试，然后进行临床试验，而ANPC运行了这些试验和测试的样品，包括纵向尿液和血浆代谢监测。

理查兹教授在评论西澳研究小组的独特职位时说：“我们处于第二波状态，有机会为Covid-19做准备。我们已经在西澳建立了一个独特的平台，以收集患者数据和生物样本，以使人们能够对疾病和对治疗的反应有透彻的了解。”

Mitigating current and future threats

Understanding the pathways to infection and the biological consequences will enable the development of effective treatments and vaccines to mitigate the current threat to thousands of people across the world. This pioneering work will also prepare us for the threat of viral pandemics in the future.

由默多克大学（Murdoch University）领导的澳大利亚国家现象中心（ANPC）将改变人们的寿命，不仅在澳大利亚，而且在世界各地。ANPC的工作几乎支持生物科学的每个领域。它涉及传统的研究孤岛，并促进了一种新的，更协作的科学方法。长期，ANPC希望建立人类疾病的“全球地图集”，从而提供对地球上每个人都可以从中受益的未来健康风险的见解。ANPC是南半球同类唯一的设施，汇集了所有五所西澳大利亚大学，并领导健康和医学研究所。它与国际现象中心网络有关，并且在农业和环境科学方面也有广泛的应用。ANPC将珀斯和WA定位为精确医学的全球领导者，并使量子能够跳出预测，诊断和治疗疾病。它是默多克大学健康期货研究所的一部分。

技术和合作伙伴

ANPC配备了来自ANPC战略联盟合作伙伴Bruker Biospin和Bruker Daltonics的多个最先进的核磁共振（NMR）和质谱仪（MS）仪器。布鲁克（Bruker）是分子和材料研究的科学工具以及工业和应用分析的制造商。bob娱乐平台bob综合游戏

Phenomes

A person's phenome is a dynamic fingerprint of their unique biology resulting from the complex interactions between environmental and genetic factors. Phenomics is the study of how the environment and a person’s lifestyle interacts with their genes to influence their health and risk of disease. Metabolic phenotyping is the analysis of biological tissue and fluid to uncover the specific interactions of genetic, environmental and lifestyle factors at a molecular level.

杰里米·尼科尔森教授

An internationally renowned pioneer in metabolic phenotyping and systems medicine, Professor Nicholson leads the ANPC. He currently holds the appointment of Pro Vice Chancellor for the Health Futures Institute at Murdoch University. Professor Nicholson is a Highly Cited Scholar who has published more than 800 peer-reviewed papers on molecular aspects of body systems medicine. A Fellow of the UK Academy of Medical Sciences, Professor Nicholson comes to WA from Imperial College London where he was the founding director of the MRC-NIHR National Phenome Centre and previously Head of Surgery and Cancer. He is currently an Emeritus Professor of Biological Chemistry at Imperial College London.

Professor Elaine Holmes

Another systems medicine pioneer, Professor Holmes is a Highly Cited Scholar and a Fellow of the UK Academy of Medical Sciences. Professor Holmes also comes to WA from Imperial College London where she was previously Head of the Division of Computational and Systems. She is Professor of Computational Medicine and a Premiers’ Fellow, Australian National Phenome Centre, Murdoch University She also holds a current appointment at Imperial College London as Professor of Chemical Biology.

Ruey-Leng Loo博士

总理的中级研究员，默多克大学ANPC高级讲师。

Professor Toby Richards

Michael Lawrence Brown Chair of Surgery UWA, Honorary Professor Institute of Clinical Trial Methodology University College London, Director COVID Research Response.

Professor Merrilee Needham

默多克大学和圣母大学澳大利亚大学菲奥娜·斯坦利医院研究主任高级顾问。